Pharmacokinetics, safety, and tolerability of etrasimod (APD334) in subjects with mild, moderate, or severe hepatic impairment: a single-dose, open-label, parallel-group study

被引：2

作者：

Lee, C. ^{[1
]}

Tang, Y. ^{[1
]}

Schroeder, C. ^{[1
]}

Zhang, J. ^{[1
]}

Nguyen-Cleary, T. ^{[1
]}

Mullin, S. ^{[1
]}

Ma, M. ^{[1
]}

Lyon, N. ^{[1
]}

Grundy, J. ^{[1
]}

机构：

[1] Arena Pharmaceut Inc, San Diego, CA USA

来源：

JOURNAL OF CROHNS & COLITIS | 2021年 / 15卷

关键词：

D O I：

10.1093/ecco-jcc/jjab076.415

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

P291

引用

页码：S321 / S322

页数：4

共 50 条

[21] Open-Label Single-Dose Study to Assess the Effect of Mild and Moderate Hepatic Impairment on the Pharmacokinetics of Mirogabalin
Kenneth Duchin
Giorgio Senaldi
Vance Warren
Thomas Marbury
Kenneth Lasseter
Hamim Zahir
Clinical Drug Investigation, 2018, 38 : 1001 - 1009
[22] Open-Label Single-Dose Study to Assess the Effect of Mild and Moderate Hepatic Impairment on the Pharmacokinetics of Mirogabalin
Duchin, Kenneth
Senaldi, Giorgio
Warren, Vance
Marbury, Thomas
Lasseter, Kenneth
Zahir, Hamim
CLINICAL DRUG INVESTIGATION, 2018, 38 (11) : 1001 - 1009
[23] Pharmacokinetics and pharmacodynamics of cinacalcet in hepatic impairment - Phase I, open-label, parallel-group, single-dose, single-centre study
Padhi, Desmond
Harris, Robert Z.
Salfi, Margaret
Noveck, Robert J.
Sullivan, John T.
CLINICAL DRUG INVESTIGATION, 2008, 28 (10) : 635 - 643
[24] EFFECT OF HEPATIC IMPAIRMENT ON COBIMETINIB PHARMACOKINETICS: AN OPEN-LABEL, SINGLE-DOSE, PARALLEL GROUP STUDY.
Templeton, I.
Kshirsagar, S.
Deng, Y.
Choong, N.
Chang, I.
Georgescu, I.
Musib, L.
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2016, 99 : S102 - S102
[25] SINGLE-DOSE SAFETY AND PHARMACOKINETICS OF APIXABAN IN SUBJECTS WITH MILD OR MODERATE HEPATIC IMPAIRMENT
Frost, C. E.
Yu, Z.
Wang, J.
Li, T.
Zeigler, C.
Schuster, A.
Ly, V.
Zhang, D.
LaCreta, F.
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2009, 85 : S34 - S34
[26] Rimegepant 75 mg in Subjects with Hepatic Impairment: Results of a Phase 1, Open-label, Single-dose, Parallel-group Study
Croop, R.
Stringfellow, J.
Ivans, A.
Coric, V
HEADACHE, 2019, 59 : 178 - 178
[27] Results of a Phase 1, Open-label, Single-dose, Parallel-group Study of Rimegepant 75 mg in Subjects with Hepatic Impairment
Ivans, Andrea
Stringfellow, Joseph
Coric, Vladimir
Croop, Robert
NEUROLOGY, 2020, 94 (15)
[28] Results of a Phase 1, Open-label, Single-dose, Parallel-group Study of Rimegepant 75 mg in Subjects with Hepatic Impairment
Croop, Robert
Stringfellow, Joseph
Ivans, Andrea
Coric, Vladimir
CEPHALALGIA, 2019, 39 : 200 - 200
[29] Rimegepant 75 mg in Subjects With Hepatic Impairment: Results of a Phase 1, Open-Label, Single-Dose, Parallel-Group Study
Bhardwaj, Rajinder
Ivans, Andrea
Stringfellow, Joseph
Morris, Beth
Coric, Vladimir
Croop, Robert
Bertz, Richard
CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2023, 12 (08): : 790 - 800
[30] Pharmacokinetics and Safety of Single-Dose Esaxerenone in Japanese Subjects with Mild to Moderate Hepatic Impairment
Akifumi Kurata
Takafumi Yoshida
Megumi Inoue
Tomoko Ishizuka
Takafumi Nakatsu
Takako Shimizu
Manabu Kato
Yasuhiro Nishikawa
Hitoshi Ishizuka
Advances in Therapy, 2020, 37 : 253 - 264

← 1 2 3 4 5 →